What is Micreos?
Micreos operates at the forefront of precision medicine, specializing in the development of recombinant proteins designed to address chronic skin conditions. Unlike traditional broad-spectrum antibiotics, the company's engineered endolysin technology offers a highly selective mechanism of action. By specifically targeting and eliminating harmful pathogens such as Staphylococcus aureus, Micreos preserves the integrity of the skin's natural microbiome, a critical factor in managing long-term dermatological health.
The company's market position is defined by its commitment to addressing significant unmet medical needs through scientific rigor. By leveraging its unique platform, Micreos is effectively bridging the gap between fundamental biotechnology research and practical, patient-centric therapeutic solutions. This focus on microbiome-friendly interventions positions the firm as a disruptive force within the global dermatology market.
How much funding has Micreos raised?
Micreos has raised a total of $108.6M across 4 funding rounds:
Private Equity
$13.4M
Unspecified
$33.8M
Unspecified
$37.1M
Other Financing Round
$24.4M
Private Equity (2016): $13.4M, investors not publicly disclosed
Unspecified (2019): $33.8M led by Undisclosed
Unspecified (2021): $37.1M, investors not publicly disclosed
Other Financing Round (2022): $24.4M, investors not publicly disclosed
Key Investors in Micreos
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for Micreos?
With the recent capital deployment, Micreos is strategically positioned to advance its lead molecule, MEndoB, toward critical clinical milestones. The roadmap for the next 24 to 36 months is centered on rigorous trial preparation, with the company aiming to initiate clinical trials by late 2026. This phase of development will be pivotal in validating the efficacy and safety profile of their endolysin-based approach in human subjects.
Looking ahead, the company is actively seeking strategic partnerships that align with its vision of revolutionizing dermatological treatments. By fostering collaborations with industry leaders and research institutions, Micreos intends to scale its operational capacity and navigate the complex regulatory landscape of pharmaceutical development. The successful execution of these clinical objectives will be essential for the company to transition into a commercial-stage entity, ultimately providing new hope for patients suffering from persistent skin conditions.
